TY - JOUR AU - Kyle, R. A. AU - Rajkumar, S. V. PY - 2004 DA - 2004// TI - Multiple myeloma JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMra041875 DO - 10.1056/NEJMra041875 ID - Kyle2004 ER - TY - JOUR AU - Sonneveld, P. AU - Schmidt-Wolf, I. G. AU - Holt, B. AU - Jarari, L. AU - Bertsch, U. AU - Salwender, H. PY - 2012 DA - 2012// TI - Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.6820 DO - 10.1200/JCO.2011.39.6820 ID - Sonneveld2012 ER - TY - JOUR AU - Hulin, C. y. r. i. l. l. e. AU - Belch, A. n. d. r. e. w. AU - Shustik, C. h. a. i. m. AU - Petrucci, M. a. r. i. a. T. e. r. e. s. a. AU - Dührsen, U. l. r. i. c. h. AU - Lu, J. i. n. AU - Song, K. e. v. i. n. AU - Rodon, P. h. i. l. i. p. p. e. AU - Pégourié, B. r. i. g. i. t. t. e. AU - Garderet, L. a. u. r. e. n. t. AU - Hunter, H. a. n. n. a. h. AU - Azais, I. s. a. b. e. l. l. e. AU - Eek, R. i. c. h. a. r. d. AU - Gisslinger, H. e. i. n. z. AU - Macro, M. a. r. g. a. r. e. t. AU - Dakhil, S. h. a. k. e. r. AU - Goncalves, C. r. i. s. t. i. n. a. AU - LeBlanc, R. i. c. h. a. r. d. AU - Romeril, K. e. n. AU - Royer, B. r. u. n. o. AU - Doyen, C. h. a. n. t. a. l. AU - Leleu, X. a. v. i. e. r. AU - Offner, F. r. i. t. z. AU - Leupin, N. i. c. o. l. a. s. AU - Houck, V. a. n. e. s. s. a. AU - Chen, G. u. a. n. g. AU - Ervin-Haynes, A. n. n. e. t. t. e. AU - Dimopoulos, M. e. l. e. t. i. o. s. A. AU - Facon, T. h. i. e. r. r. y. PY - 2016 DA - 2016// TI - Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial JO - Journal of Clinical Oncology VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.7295 DO - 10.1200/JCO.2016.66.7295 ID - Hulin2016 ER - TY - JOUR AU - Lokhorst, H. M. AU - Plesner, T. AU - Laubach, J. P. AU - Nahi, H. AU - Gimsing, P. AU - Hansson, M. PY - 2015 DA - 2015// TI - Targeting CD38 with daratumumab monotherapy in multiple myeloma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1506348 DO - 10.1056/NEJMoa1506348 ID - Lokhorst2015 ER - TY - JOUR AU - Child, J. A. AU - Morgan, G. J. AU - Davies, F. E. AU - Owen, R. G. AU - Bell, S. E. AU - Hawkins, K. PY - 2003 DA - 2003// TI - High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa022340 DO - 10.1056/NEJMoa022340 ID - Child2003 ER - TY - JOUR AU - Barlogie, B. AU - Mitchell, A. AU - Rhee, F. AU - Epstein, J. AU - Morgan, G. J. AU - Crowley, J. PY - 2014 DA - 2014// TI - Curing myeloma at last: defining criteria and providing the evidence JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-07-552059 DO - 10.1182/blood-2014-07-552059 ID - Barlogie2014 ER - TY - JOUR AU - Goldschmidt, H. AU - Lokhorst, H. M. AU - Mai, E. K. AU - Holt, B. AU - Blau, I. W. AU - Zweegman, S. PY - 2018 DA - 2018// TI - Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial JO - Leukemia VL - 32 UR - https://doi.org/10.1038/leu.2017.211 DO - 10.1038/leu.2017.211 ID - Goldschmidt2018 ER - TY - JOUR AU - Jethava, Y. AU - Mitchell, A. AU - Zangari, M. AU - Waheed, S. AU - Schinke, C. AU - Thanendrarajan, S. PY - 2016 DA - 2016// TI - Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma JO - Blood Cancer J VL - 6 UR - https://doi.org/10.1038/bcj.2016.85 DO - 10.1038/bcj.2016.85 ID - Jethava2016 ER - TY - JOUR AU - Kumar, S. K. AU - Mikhael, J. R. AU - Buadi, F. K. AU - Dingli, D. AU - Dispenzieri, A. AU - Fonseca, R. PY - 2009 DA - 2009// TI - Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines JO - Mayo Clin Proc VL - 84 UR - https://doi.org/10.4065/mcp.2009.0603 DO - 10.4065/mcp.2009.0603 ID - Kumar2009 ER - TY - JOUR AU - Palumbo, A. AU - Avet-Loiseau, H. AU - Oliva, S. AU - Lokhorst, H. M. AU - Goldschmidt, H. AU - Rosinol, L. PY - 2015 DA - 2015// TI - Revised international staging system for multiple myeloma: a report from International Myeloma Working Group JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.2267 DO - 10.1200/JCO.2015.61.2267 ID - Palumbo2015 ER - TY - JOUR AU - Neben, K. AU - Jauch, A. AU - Bertsch, U. AU - Heiss, C. AU - Hielscher, T. AU - Seckinger, A. PY - 2010 DA - 2010// TI - Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.016436 DO - 10.3324/haematol.2009.016436 ID - Neben2010 ER - TY - JOUR AU - Avet-Loiseau, H. AU - Durie, B. G. AU - Cavo, M. AU - Attal, M. AU - Gutierrez, N. AU - Haessler, J. PY - 2013 DA - 2013// TI - Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.282 DO - 10.1038/leu.2012.282 ID - Avet-Loiseau2013 ER - TY - JOUR AU - Hose, D. AU - Reme, T. AU - Hielscher, T. AU - Moreaux, J. AU - Meissner, T. AU - Seckinger, A. PY - 2011 DA - 2011// TI - Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma JO - Haematologica VL - 96 UR - https://doi.org/10.3324/haematol.2010.030296 DO - 10.3324/haematol.2010.030296 ID - Hose2011 ER - TY - JOUR AU - Shaughnessy, J. D. AU - Zhan, F. AU - Burington, B. E. AU - Huang, Y. AU - Colla, S. AU - Hanamura, I. PY - 2007 DA - 2007// TI - A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-07-038430 DO - 10.1182/blood-2006-07-038430 ID - Shaughnessy2007 ER - TY - JOUR AU - Decaux, O. AU - Lodé, L. AU - Magrangeas, F. AU - Charbonnel, C. AU - Gouraud, W. AU - Jézéquel, P. PY - 2008 DA - 2008// TI - Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.8545 DO - 10.1200/JCO.2007.13.8545 ID - Decaux2008 ER - TY - JOUR AU - Reme, T. AU - Hose, D. AU - Theillet, C. AU - Klein, B. PY - 2013 DA - 2013// TI - Modeling risk stratification in human cancer JO - Bioinformatics VL - 29 UR - https://doi.org/10.1093/bioinformatics/btt124 DO - 10.1093/bioinformatics/btt124 ID - Reme2013 ER - TY - JOUR AU - Kuiper, R. AU - Broyl, A. AU - Knegt, Y. AU - Vliet, M. H. AU - Beers, E. H. AU - Holt, B. PY - 2012 DA - 2012// TI - A gene expression signature for high-risk multiple myeloma JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2012.127 DO - 10.1038/leu.2012.127 ID - Kuiper2012 ER - TY - JOUR AU - Chng, W. J. AU - Chung, T. H. AU - Kumar, S. AU - Usmani, S. AU - Munshi, N. AU - Avet-Loiseau, H. PY - 2016 DA - 2016// TI - Gene signature combinations improve prognostic stratification of multiple myeloma patients JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.341 DO - 10.1038/leu.2015.341 ID - Chng2016 ER - TY - JOUR AU - Chng, W. J. AU - Dispenzieri, A. AU - Chim, C. S. AU - Fonseca, R. AU - Goldschmidt, H. AU - Lentzsch, S. PY - 2014 DA - 2014// TI - IMWG consensus on risk stratification in multiple myeloma JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.247 DO - 10.1038/leu.2013.247 ID - Chng2014 ER - TY - JOUR AU - Fonseca, R. AU - Bergsagel, P. L. AU - Drach, J. AU - Shaughnessy, J. AU - Gutierrez, N. AU - Stewart, A. K. PY - 2009 DA - 2009// TI - International Myeloma Working Group molecular classification of multiple myeloma: spotlight review JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2009.174 DO - 10.1038/leu.2009.174 ID - Fonseca2009 ER - TY - JOUR AU - Hose, D. AU - Rème, T. AU - Meissner, T. AU - Moreaux, J. AU - Seckinger, A. AU - Lewis, J. PY - 2009 DA - 2009// TI - Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-09-178350 DO - 10.1182/blood-2008-09-178350 ID - Hose2009 ER - TY - JOUR AU - Sprynski, A. C. AU - Hose, D. AU - Caillot, L. AU - Reme, T. AU - Shaughnessy, J. D. AU - Barlogie, B. PY - 2009 DA - 2009// TI - The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-07-170464 DO - 10.1182/blood-2008-07-170464 ID - Sprynski2009 ER - TY - JOUR AU - Jethava, Y. S. AU - Mitchell, A. AU - Epstein, J. AU - Zangari, M. AU - Yaccoby, S. AU - Tian, E. PY - 2017 DA - 2017// TI - Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-15-2620 DO - 10.1158/1078-0432.CCR-15-2620 ID - Jethava2017 ER - TY - JOUR AU - Neben, K. AU - Lokhorst, H. M. AU - Jauch, A. AU - Bertsch, U. AU - Hielscher, T. AU - Holt, B. PY - 2012 DA - 2012// TI - Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-09-379164 DO - 10.1182/blood-2011-09-379164 ID - Neben2012 ER - TY - STD TI - Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019:JCO1800776. ID - ref25 ER - TY - JOUR AU - Hofste op Bruinink, D. AU - Duin, M. AU - Beksac, M. AU - Driessen, C. AU - Ludwig, H. AU - Vermeulen, M. PY - 2018 DA - 2018// TI - Differential effect of upfront intensification treatment in genetically defined myeloma risk groups—a combined analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial JO - Blood VL - 132 ID - Hofste op Bruinink2018 ER - TY - JOUR AU - Sherborne, A. L. AU - Shah, V. AU - Ellis, S. AU - Begum, F. AU - Kendall, J. AU - Johnson, D. C. PY - 2017 DA - 2017// TI - Improving outcomes for patients with high-risk myeloma via prospective trial evidence: The Myeloma UK Nine Optimum Trial JO - Blood VL - 130 ID - Sherborne2017 ER - TY - JOUR AU - Beers, E. H. AU - Terragna, C. AU - Martello, M. AU - Zamagni, E. AU - Cavo, M. AU - Vliet, M. H. PY - 2017 DA - 2017// TI - Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006 JO - Blood VL - 130 ID - Beers2017 ER - TY - JOUR AU - Mai, E. K. AU - Bertsch, U. AU - Durig, J. AU - Kunz, C. AU - Haenel, M. AU - Blau, I. W. PY - 2015 DA - 2015// TI - Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma JO - Leukemia VL - 29 UR - https://doi.org/10.1038/leu.2015.80 DO - 10.1038/leu.2015.80 ID - Mai2015 ER - TY - JOUR AU - Hose, D. AU - Moreaux, J. AU - Meissner, T. AU - Seckinger, A. AU - Goldschmidt, H. AU - Benner, A. PY - 2009 DA - 2009// TI - Induction of angiogenesis by normal and malignant plasma cells JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2008-10-184226 DO - 10.1182/blood-2008-10-184226 ID - Hose2009 ER - TY - JOUR AU - Meißner, T. AU - Seckinger, A. AU - Rème, T. AU - Hielscher, T. AU - Möhler, T. AU - Neben, K. PY - 2011 DA - 2011// TI - Gene expression profiling in multiple myeloma—reporting of entities, risk, and targets in clinical routine JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-1628 DO - 10.1158/1078-0432.CCR-11-1628 ID - Meißner2011 ER - TY - JOUR AU - Seckinger, A. AU - Delgado, J. A. AU - Moser, S. AU - Moreno, L. AU - Neuber, B. AU - Grab, A. PY - 2017 DA - 2017// TI - Target expression, generation, preclinical activity, and Pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment JO - Cancer Cell VL - 31 UR - https://doi.org/10.1016/j.ccell.2017.02.002 DO - 10.1016/j.ccell.2017.02.002 ID - Seckinger2017 ER - TY - JOUR AU - Seckinger, A. AU - Meißner, T. AU - Moreaux, J. AU - Depeweg, D. AU - Hillengass, J. AU - Hose, K. PY - 2012 DA - 2012// TI - Clinical and prognostic role of annexin A2 in multiple myeloma JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-03-415588 DO - 10.1182/blood-2012-03-415588 ID - Seckinger2012 ER - TY - JOUR AU - Seckinger, A. AU - Meissner, T. AU - Moreaux, J. AU - Goldschmidt, H. AU - Fuhler, G. M. AU - Benner, A. PY - 2009 DA - 2009// TI - Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis JO - Oncogene VL - 28 UR - https://doi.org/10.1038/onc.2009.257 DO - 10.1038/onc.2009.257 ID - Seckinger2009 ER - TY - STD TI - Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, et al. CD38 as Immunotherapeutic target in light chain amyloidosis and multiple myeloma—association with molecular entities, risk, survival, and mechanisms of upfront resistance. Frontiers in Immunology. 2018;9. ID - ref35 ER - TY - JOUR AU - Neben, K. AU - Jauch, A. AU - Hielscher, T. AU - Hillengass, J. AU - Lehners, N. AU - Seckinger, A. PY - 2013 DA - 2013// TI - Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.4923 DO - 10.1200/JCO.2012.48.4923 ID - Neben2013 ER - TY - BOOK PY - 2008 DA - 2008// TI - R: A language and environment for statistical computing PB - R Foundation for Statistical Computing CY - Vienna ID - ref37 ER - TY - JOUR AU - Gentleman, R. C. AU - Carey, V. J. AU - Bates, D. M. AU - Bolstad, B. AU - Dettling, M. AU - Dudoit, S. PY - 2004 DA - 2004// TI - Bioconductor: open software development for computational biology and bioinformatics JO - Genome Biol VL - 5 UR - https://doi.org/10.1186/gb-2004-5-10-r80 DO - 10.1186/gb-2004-5-10-r80 ID - Gentleman2004 ER - TY - JOUR AU - Bergsagel, P. L. AU - Kuehl, W. M. AU - Zhan, F. AU - Sawyer, J. AU - Barlogie, B. AU - Shaughnessy, J. PY - 2005 DA - 2005// TI - Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-01-0034 DO - 10.1182/blood-2005-01-0034 ID - Bergsagel2005 ER - TY - JOUR AU - Hose, D. AU - Rossi, J. -. F. AU - Ittrich, C. AU - DeVos, J. AU - RŠme, T. AU - Benner, A. PY - 2005 DA - 2005// TI - Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). [abstract] JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-01-0023 DO - 10.1182/blood-2005-01-0023 ID - Hose2005 ER - TY - JOUR AU - Zhan, F. AU - Huang, Y. AU - Colla, S. AU - Stewart, J. P. AU - Hanamura, I. AU - Gupta, S. PY - 2006 DA - 2006// TI - The molecular classification of multiple myeloma JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2005-11-013458 DO - 10.1182/blood-2005-11-013458 ID - Zhan2006 ER - TY - JOUR AU - Tibshirani, R. AU - Hastie, T. AU - Narasimhan, B. AU - Chu, G. PY - 2002 DA - 2002// TI - Diagnosis of multiple cancer types by shrunken centroids of gene expression JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.082099299 DO - 10.1073/pnas.082099299 ID - Tibshirani2002 ER - TY - STD TI - Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Modeling Survival Data: Extending the Cox Model: Springer-Verlag, New York; 2000. p. XIV, 350. ID - ref43 ER - TY - JOUR AU - Andersen, P. K. AU - Gill, R. D. PY - 1982 DA - 1982// TI - Cox's Regression Model for Counting Processes: A Large Sample Study JO - Annals of Statistics VL - 10 UR - https://doi.org/10.1214/aos/1176345976 DO - 10.1214/aos/1176345976 ID - Andersen1982 ER - TY - JOUR AU - Fleming, T. R. AU - Harrington, D. P. PY - 1984 DA - 1984// TI - Nonparametric estimation of the survival distribution in censored data JO - Comm in Stat Theory and Methods VL - 13 UR - https://doi.org/10.1080/03610928408828837 DO - 10.1080/03610928408828837 ID - Fleming1984 ER - TY - JOUR AU - Kaplan, E. L. AU - Meier, P. PY - 1958 DA - 1958// TI - Nonparametric estimation from incomplete observations JO - Journal of the American Statistical Association VL - 53 UR - https://doi.org/10.1080/01621459.1958.10501452 DO - 10.1080/01621459.1958.10501452 ID - Kaplan1958 ER - TY - JOUR AU - Harrington, D. P. AU - Fleming, T. R. PY - 1982 DA - 1982// TI - A class of rank test procedures for censored survival data JO - Biometrika VL - 69 UR - https://doi.org/10.1093/biomet/69.3.553 DO - 10.1093/biomet/69.3.553 ID - Harrington1982 ER - TY - JOUR AU - Schumacher, M. AU - Graf, E. AU - Gerds, T. PY - 2003 DA - 2003// TI - How to assess prognostic models for survival data: a case study in oncology JO - Methods Inf Med VL - 42 UR - https://doi.org/10.1055/s-0038-1634384 DO - 10.1055/s-0038-1634384 ID - Schumacher2003 ER - TY - JOUR AU - Mogensen, U. B. AU - Ishwaran, H. AU - Gerds, T. A. PY - 2012 DA - 2012// TI - Evaluating random forests for survival analysis using prediction error curves JO - Journal of statistical software VL - 50 UR - https://doi.org/10.18637/jss.v050.i11 DO - 10.18637/jss.v050.i11 ID - Mogensen2012 ER - TY - JOUR AU - Wiel, M. A. AU - Berkhof, J. AU - Wieringen, W. N. PY - 2009 DA - 2009// TI - Testing the prediction error difference between 2 predictors JO - Biostatistics VL - 10 UR - https://doi.org/10.1093/biostatistics/kxp011 DO - 10.1093/biostatistics/kxp011 ID - Wiel2009 ER - TY - JOUR AU - Nilsson, T. AU - Hoglund, M. AU - Lenhoff, S. AU - Rylander, L. AU - Turesson, I. AU - Westin, J. PY - 2003 DA - 2003// TI - A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences JO - Br J Haematol VL - 120 UR - https://doi.org/10.1046/j.1365-2141.2003.04221.x DO - 10.1046/j.1365-2141.2003.04221.x ID - Nilsson2003 ER - TY - JOUR AU - Cavo, M. AU - Beksac, M. AU - Dimopoulos, M. A. AU - Pantani, L. AU - Gay, F. AU - Hájek, R. PY - 2016 DA - 2016// TI - Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial) JO - Blood VL - 128 ID - Cavo2016 ER - TY - JOUR AU - Attal, M. AU - Lauwers-Cances, V. AU - Hulin, C. AU - Leleu, X. AU - Caillot, D. AU - Escoffre, M. PY - 2017 DA - 2017// TI - Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1611750 DO - 10.1056/NEJMoa1611750 ID - Attal2017 ER - TY - JOUR AU - Einsele, H. AU - Engelhardt, M. AU - Tapprich, C. AU - Muller, J. AU - Liebisch, P. AU - Langer, C. PY - 2017 DA - 2017// TI - Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial JO - Br J Haematol VL - 179 UR - https://doi.org/10.1111/bjh.14920 DO - 10.1111/bjh.14920 ID - Einsele2017 ER - TY - JOUR AU - Durie, B. G. AU - Hoering, A. AU - Abidi, M. H. AU - Rajkumar, S. V. AU - Epstein, J. AU - Kahanic, S. P. PY - 2017 DA - 2017// TI - Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)31594-X DO - 10.1016/S0140-6736(16)31594-X ID - Durie2017 ER - TY - JOUR AU - Lahuerta, J. J. AU - Paiva, B. AU - Vidriales, M. B. AU - Cordon, L. AU - Cedena, M. T. AU - Puig, N. PY - 2017 DA - 2017// TI - Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.69.2517 DO - 10.1200/JCO.2016.69.2517 ID - Lahuerta2017 ER - TY - JOUR AU - Moreau, P. AU - Cavallo, F. AU - Leleu, X. AU - Hulin, C. AU - Amiot, M. AU - Descamps, G. PY - 2011 DA - 2011// TI - Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma JO - Leukemia VL - 25 UR - https://doi.org/10.1038/leu.2011.4 DO - 10.1038/leu.2011.4 ID - Moreau2011 ER - TY - JOUR AU - Trudel, S. AU - Li, Z. H. AU - Wei, E. AU - Wiesmann, M. AU - Chang, H. AU - Chen, C. PY - 2005 DA - 2005// TI - CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-10-3913 DO - 10.1182/blood-2004-10-3913 ID - Trudel2005 ER - TY - JOUR AU - Sprynski, A. C. AU - Hose, D. AU - Kassambara, A. AU - Vincent, L. AU - Jourdan, M. AU - Rossi, J. F. PY - 2010 DA - 2010// TI - Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2010.192 DO - 10.1038/leu.2010.192 ID - Sprynski2010 ER - TY - JOUR AU - Kuiper, R. AU - Duin, M. AU - Vliet, M. H. AU - Broijl, A. AU - Holt, B. AU - Jarari, L. PY - 2015 DA - 2015// TI - Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System JO - Blood VL - 126 UR - https://doi.org/10.1182/blood-2015-05-644039 DO - 10.1182/blood-2015-05-644039 ID - Kuiper2015 ER - TY - JOUR AU - Sherborne, A. L. AU - Begum, D. B. AU - Price, A. AU - Johnson, D. C. AU - Ellis, S. AU - Smith, C. PY - 2016 DA - 2016// TI - Identifying ultra-high risk myeloma by integrated molecular genetic and gene expression profiling JO - Blood VL - 128 ID - Sherborne2016 ER - TY - JOUR AU - Zhou, Y. AU - Zhang, Q. AU - Stephens, O. AU - Heuck, C. J. AU - Tian, E. AU - Sawyer, J. R. AU - Cartron-Mizeracki, M. -. A. AU - Qu, P. AU - Keller, J. AU - Epstein, J. AU - Barlogie, B. AU - Shaughnessy, J. D. PY - 2012 DA - 2012// TI - Prediction of cytogenetic abnormalities with gene expression profiles JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-388702 DO - 10.1182/blood-2011-10-388702 ID - Zhou2012 ER - TY - CHAP AU - Seckinger, A. n. j. a. AU - Bähr-Ivacevic, T. o. m. i. AU - Benes, V. l. a. d. i. m. i. r. AU - Hose, D. i. r. k. PY - 2018 DA - 2018// TI - RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine BT - Methods in Molecular Biology PB - Springer New York CY - New York, NY ID - Seckinger2018 ER - TY - JOUR AU - Xu, J. AU - Thakkar, S. AU - Gong, B. AU - Tong, W. PY - 2016 DA - 2016// TI - The FDAʼs experience with emerging genomics technologies-past, present, and future JO - AAPS J VL - 18 UR - https://doi.org/10.1208/s12248-016-9917-y DO - 10.1208/s12248-016-9917-y ID - Xu2016 ER - TY - JOUR AU - Seckinger, A. AU - Meissner, T. AU - Moreaux, J. AU - Benes, V. AU - Hillengass, J. AU - Castoldi, M. PY - 2015 DA - 2015// TI - miRNAs in multiple myeloma—a survival relevant complex regulator of gene expression JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.5381 DO - 10.18632/oncotarget.5381 ID - Seckinger2015 ER - TY - JOUR AU - Conesa, A. AU - Madrigal, P. AU - Tarazona, S. AU - Gomez-Cabrero, D. AU - Cervera, A. AU - McPherson, A. PY - 2016 DA - 2016// TI - A survey of best practices for RNA-seq data analysis JO - Genome Biol VL - 17 UR - https://doi.org/10.1186/s13059-016-0881-8 DO - 10.1186/s13059-016-0881-8 ID - Conesa2016 ER - TY - JOUR AU - Costa-Silva, J. AU - Domingues, D. AU - Lopes, F. M. PY - 2017 DA - 2017// TI - RNA-Seq differential expression analysis: an extended review and a software tool JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0190152 DO - 10.1371/journal.pone.0190152 ID - Costa-Silva2017 ER -